EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells

Guan-Ling Lin, Jen-Che Chang, Yue-Cen Lai, Te-Sheng Lien, Der-Shan Sun, Ching-Feng Cheng, Lian-Fu Yang, Ruo-Chia Tseng, Yu-Jui Su, Hsin-Ying Wu, Tzenge-Lien Shih, Hsin-Hou Chang

International Journal of Molecular Sciences · 16.11.2026 · 27 (22) · 10279

DOI: 10.3390/ijms272210279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.11.2026. Verfasst von Guan-Ling Lin und 11 weiteren Autor:innen. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Tzu-Chi Medical Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.

Förderung

  • National Science and Technology Council
  • Tzu-Chi Medical Foundation

Zitieren

APA

Lin, G., Chang, J., Lai, Y., Lien, T., Sun, D., Cheng, C., Yang, L., Tseng, R., Su, Y., Wu, H., Shih, T., & Chang, H. (2026). Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells. International Journal of Molecular Sciences, 27(22), 10279. https://doi.org/10.3390/ijms272210279

Vancouver

Lin G, Chang J, Lai Y, Lien T, Sun D, Cheng C, et al. Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells. International Journal of Molecular Sciences. 2026;27(22):10279. doi:10.3390/ijms272210279

BibTeX
@article{Lin2026,
  author = {Lin, Guan-Ling and Chang, Jen-Che and Lai, Yue-Cen and Lien, Te-Sheng and Sun, Der-Shan and Cheng, Ching-Feng and Yang, Lian-Fu and Tseng, Ruo-Chia and Su, Yu-Jui and Wu, Hsin-Ying and Shih, Tzenge-Lien and Chang, Hsin-Hou},
  title = {Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10279},
  doi = {10.3390/ijms272210279}
}
Kostenlos starten →